Allergan, FDA To Meet On Tazoral NDA Deficiencies By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting follows a Sept. 24 "not approvable" letter for the psoriasis treatment tazarotene. Allergan says the meeting is needed to provide insight into trial design for a non-inferiority trial.